# Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)

Source: https://onco.cc/trials/nct06634875/  
OnCo record `nct06634875` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of isunakinra in colorectal cancer, run by Buzzard Pharmaceuticals, now recruiting.

## Summary

Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS) is a phase 2 interventional study registered as NCT06634875 by Buzzard Pharmaceuticals, with 20 participants planned, started 2025-01-30 and due to reach its primary completion in 2026-06. Interventions recorded: isunakinra.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06634875
- Phase: 2
- Setting: A Phase IIa, Non-Randomized, Open-Label Dose Expansion Trial of Isunakinra in Combination With Pembrolizumab in Patients With Metastatic or Unresectable, Locally Advanced Colorectal Cancer
- Sponsor: Buzzard Pharmaceuticals
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT06634875: https://clinicaltrials.gov/study/NCT06634875

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)

---
JSON: https://onco.cc/api/v1/entities/nct06634875.json